More bad news for those that have disease with no treatment By: MarketWatch April 26, 2016 at 15:33 PM EDT FDA panel voted not to give Sarepta’s Duchenne muscular dystrophy drug a recommendation. Read More >> Related Stocks: Biomarin Pharmaceuticals Sarepta Therapeutics